Best Life Sciences Companies in Bothell, United States

Biopharmaceutical company pioneering subcutaneous therapies for liver disease and cancer. Focused on developing novel treatments for patients with advanced liver cirrhosis and cancer, this clinical-stage company leverages expertise in target-specific biology and peptide engineering. They are dedicated to improving patient outcomes through innovative, self-injectable therapies designed for effective and easily administered treatments. Their drug development programs target chronic and complex conditions, providing solutions that enable patients to manage their health more effectively and independently. They are committed to transforming lives by providing therapeutic solutions that address urgent unmet medical needs, particularly in outpatient care, enabling patients to manage their health with greater ease and confidence. They are actively seeking strategic partnerships to advance clinical development and commercialization.

Provider of tests to prevent, treat, and cure chronic diseases, and cancer. It uses AI and proprietary mRNA sequencing technology to develop a CancerDetect test for oral & throat cancer. The company platform enables to development of predictive biomarkers, precision diagnostics, and precision therapeutics to prevent and intercept chronic diseases. It has also developed 30 predictive models for Glycemic response, Obesity, Diabetes, Depression, IBS, and Oral Cancer.

Funding rounds

• Aug 2024Series C$25.4M
• Oct 2022Series C$67M

Founders & team

Momchilo VuyisichCo-Founder & Chief Science OfficerNaveen JainFounder & CEO

Investors

BOLD Capital Group, Khosla Ventures, WestRiver Group, Glico Group, Ocgrow Group of Companies, Physician Partners

Tech stack

Amazon Web ServicesGoogle AnalyticsGoogle Tag ManagerHstsKetchNext.Js

Developer of antibody-drug conjugates for the treatment of cancer. The company's products include Brentuximab vedotin targets CD30 found on the surface of Hodgkin lymphoma cells, Enfortumab vedotin for bladder cancer, Tucatinib for multiple cancers, Tisotumab vedotin targets tissue factors on solid tumors, Ladiratuzumab vedotin targets LIV-1, and others.

Developer of cell and gene therapies with the integrity of a single cell. The company provides biopreservation media like CryoStor Freeze Media, which supports clinical applications and maximizes post-thaw cell viability. Additional solutions include HypoThermosol for hypothermic storage, ThawSTAR automated thawing devices, and closed-system cell processing tools.

Ventec Life Systems is a developer of respiratory devices used in the ICU setting. It develops and manufactures life support ventilators for patients with respiratory diseases. The company offers ventilators, nebulizers, portable oxygen concentrators, cough assist devices, suction unit - five systems integrated with one. The company received FDA clearance for its VOCSN Unified Respiratory System. It is intended to provide continuous or intermittent ventilatory support for the care of individuals who require mechanical ventilation.

Humanized monoclonal antibody based therapeutics for migraine and inflammatory diseases

Point-of-care ultrasound solutions provider, empowering clinicians with advanced imaging. The company delivers intuitive, dependable, and user-friendly ultrasound devices designed for diverse clinical settings. They offer a portfolio of ultrasound systems, transducers, accessories, and educational resources. Their solutions support procedural workflows, streamline diagnosis, and prioritize patient care. They provide advanced digital imaging to healthcare professionals and organizations globally. They are focused on producing the best ultrasound image at the point of care. They offer training, service, and support to ensure optimal use of their products. They are committed to innovation and collaboration with clinicians to address medical challenges. They provide solutions for point-of-care ultrasound (POCUS), offering advanced image clarity and workflow efficiency. They offer software solutions to help clinicians meet administrative challenges by enabling standardized remote workflows related to credentialing, quality assurance (QA), and coding, while ultimately improving patient care.

Developer of a device for thrombolysis to treat pulmonary embolism. The EkoSonic Endovascular System is used in dissolving clots with its first generation of ultrasound thrombolytic technology. The acoustic energy from the device conditions clots by thinning fibrin, increasing porosity, and creating a pressure gradient that transports clot-dissolving drug deep inside the occluding thrombus. The company's products are used in the treatment of Deep Vein Thrombosis, Pulmonary embolism, and Peripheral arterial occlusion.

Mirabilis Medical provides a non-invasive diagnostic and therapeutic ultrasound system. The system is meant for diagnosis and application to the treatment of uterine fibroids. The system provides ultrasound imaging to enable physicians to see uterine fibroids and specially developed therapeutic ultrasound technology to allow treatment of targeted fibroids without the need for invasive surgery.

Funding rounds

• Aug 2016Series C$5M
• Jun 2016Series C$5.2M
• Jun 2013Series A$7M
• May 2013Series A$50K

Founders & team

Jens QuistgaardPresident & CEO

Investors

Arboretum Ventures, Split Rock Partners, Dow Chemical Company, GSR Ventures, Charter Life Sciences, Signal Peak

Medical device company developing innovative ultrasound and microsphere therapies, focused on creating first-in-class therapeutic solutions. The company is dedicated to restoring health and improving the quality of life for patients suffering from major diseases. They leverage core expertise in ultrasound and microsphere technologies to develop novel treatments for conditions with limited options. Their clinical-stage programs target ischemic stroke and retinal vein occlusion, addressing significant unmet medical needs. They are committed to developing new treatments to address unmet medical needs, adhering to core values that drive innovation and patient well-being. Their work has a direct social impact by providing solutions for devastating diseases.

Funding rounds

• Mar 2015Series C$11.4M
• Dec 2014Series C$10M
• Mar 2014Series B$1.8M
• Apr 2013Series B$14.1M

Founders & team

Bradford ZakesChief Executive Officer

Investors

Haiyin Capital, Swiftsure

Tech stack

WordpressMysqlPhpContact Form 7LitespeedRecaptcha

Developer of medical devices for the treatment of uterine fibroids. The company develops Mirabilis System that combines high-speed therapeutic ultrasound technology with an advanced robotic system to treat uterine fibroids.

Biotech firm pioneering bioactive peptides for pharmaceutical and cosmeceutical markets. The company focuses on research and development of innovative peptide-based solutions. It has an extensive proprietary library of bioactive peptides derived from innate immunity, targeting rare dermatological diseases like xeroderma pigmentosum. The company's drug development program addresses unmet needs in this area. It seeks to build shareholder value through novel drug development. The company is involved in peptide discovery and development, with intellectual property covering a diverse range of applications. It uses an Accessibility Checker to monitor website accessibility. The company's scientific advisory board includes experts in DNA repair and mutagenesis, contributing to the development of therapeutics for sunlight-induced skin cancers.

Funding rounds

• Jul 2019Post IPO$5.6M
• Dec 2014Post IPO$1M
• Apr 2013Post IPO$500K
• Dec 2010Unattributed$599.8K

Founders & team

Robin CarmichaelPresident & CEO